Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817091 | 0.90 | SMN1; SMN2 (0.60) | TDP1HPGDALOX15HRH1SMN1; SMN2 | |
| SCHEMBL12851363 | 0.83 | HRH3 (0.56) | TDP1HPGDALOX15HRH1SMN1; SMN2 | |
| SCHEMBL966286 | 0.82 | CA1 (0.56) | TDP1HPGDALOX15SMN1; SMN2CYP1A2 | |
| SCHEMBL29672808 | 0.82 | CA1 (0.56) | TDP1HPGDALOX15SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11689290 | 0.81 | CA1 (0.55) | TDP1HPGDALOX15SMN1; SMN2CYP1A2 | |
| SCHEMBL626826 | 0.80 | HRH1 (0.57) | TDP1HPGDALOX15HRH1SMN1; SMN2 | |
| SCHEMBL6446039 | 0.78 | CYP1A2 (0.57) | TDP1HPGDALOX15HRH1SMN1; SMN2 | |
| SCHEMBL333243 | 0.78 | SMN1; SMN2 (0.62) | TDP1HPGDALOX15HRH1SMN1; SMN2 | |
| SCHEMBL29499090 | 0.78 | SMN1; SMN2 (0.62) | TDP1HPGDALOX15HRH1SMN1; SMN2 | |
| SCHEMBL28254579 | 0.78 | SMN1; SMN2 (0.50) | TDP1HPGDALOX15HRH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239765-A1 | GLYCINE N-METHYLTRANSFERASE SPECIFIC ENHANCER AND PREPARATION METHOD AND USES THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2024-07-18 | — | — | US | claimed |
| EP-4269401-A1 | GLYCINE N-METHYLTRANSFERASE ENHANCER, PREPARATION METHOD THEREFOR AND USE THEREOF | Kaohsiung Medical University (TW) | 2023-11-01 | — | — | EP | claimed |
| EP-0694546-B1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and use | SEARLE & CO (US) | 2001-06-06 | — | — | EP | claimed |
| EP-0694545-B1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | SEARLE & CO (US) | 2000-07-26 | — | — | EP | claimed |
| US-5576315-A | Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia | G.D. SEARLE & CO. (US) | 1996-11-19 | — | — | US | claimed |
| EP-0694546-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | claimed |
| EP-0694545-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | claimed |
| US-5464830-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1995-11-07 | — | — | US | claimed |
| EP-0583421-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | claimed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | claimed |
| US-20240239765-A1 | GLYCINE N-METHYLTRANSFERASE SPECIFIC ENHANCER AND PREPARATION METHOD AND USES THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2024-07-18 | — | — | US | disclosed |
| EP-4269401-A1 | GLYCINE N-METHYLTRANSFERASE ENHANCER, PREPARATION METHOD THEREFOR AND USE THEREOF | Kaohsiung Medical University (TW) | 2023-11-01 | — | — | EP | disclosed |
| CN-105237504-B | Nitrogenous analog derivative of myricetin and its preparation method and application | 贵州大学 | 2018-07-06 | — | — | CN | disclosed |
| EP-0694546-B1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and use | SEARLE & CO (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-0694545-B1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | SEARLE & CO (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0694545-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5464830-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5378840-A | Substituted dibenzoxazepine compounds | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239765-A1 | GLYCINE N-METHYLTRANSFERASE SPECIFIC ENHANCER AND PREPARATION METHOD AND USES THEREOF | GNMT, NNMT, HNMT | TDP1 1882/4885HPGD 404/4885ALOX15 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.